{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T04:56:54Z","timestamp":1771477014033,"version":"3.50.1"},"reference-count":55,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2017,1,13]],"date-time":"2017-01-13T00:00:00Z","timestamp":1484265600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1"},{"start":{"date-parts":[[2017,1,13]],"date-time":"2017-01-13T00:00:00Z","timestamp":1484265600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions"}],"funder":[{"DOI":"10.13039\/501100001807","name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado de S\u00e3o Paulo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001807","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharmacology"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1002\/jcph.863","type":"journal-article","created":{"date-parts":[[2017,1,13]],"date-time":"2017-01-13T15:15:50Z","timestamp":1484320550000},"page":"784-795","source":"Crossref","is-referenced-by-count":5,"title":["Enantioselectivity in the Metabolism of Cyclophosphamide in Patients With Multiple or Systemic Sclerosis"],"prefix":"10.1002","volume":"57","author":[{"given":"Francine Atti\u00e9","family":"de Castro","sequence":"first","affiliation":[{"name":"Departamento de An\u00e1lises Cl\u00ednicas, Toxicol\u00f3gicas e Bromatol\u00f3gicas; Faculdade de Ci\u00eancias Farmac\u00eauticas de Ribeir\u00e3o Preto; Universidade de S\u00e3o Paulo; Ribeir\u00e3o Preto S\u00e3o Paulo Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Belinda Pinto","family":"Sim\u00f5es","sequence":"additional","affiliation":[{"name":"Departamento de Cl\u00ednica M\u00e9dica; Faculdade de Medicina de Ribeir\u00e3o Preto; Universidade de S\u00e3o Paulo; Ribeir\u00e3o Preto S\u00e3o Paulo Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduardo Barbosa","family":"Coelho","sequence":"additional","affiliation":[{"name":"Departamento de Cl\u00ednica M\u00e9dica; Faculdade de Medicina de Ribeir\u00e3o Preto; Universidade de S\u00e3o Paulo; Ribeir\u00e3o Preto S\u00e3o Paulo Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vera Lucia","family":"Lanchote","sequence":"additional","affiliation":[{"name":"Departamento de An\u00e1lises Cl\u00ednicas, Toxicol\u00f3gicas e Bromatol\u00f3gicas; Faculdade de Ci\u00eancias Farmac\u00eauticas de Ribeir\u00e3o Preto; Universidade de S\u00e3o Paulo; Ribeir\u00e3o Preto S\u00e3o Paulo Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,1,13]]},"reference":[{"issue":"2","key":"10.1002\/jcph.863-BIB0001|jcph863-cit-0001","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/bmt.2009.127","article-title":"Brazilian experience with two conditioning regimens in patients with multiple sclerosis: BEAM\/horse ATG and CY\/rabbit ATG","volume":"45","author":"Hamerschlak","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1002\/jcph.863-BIB0002|jcph863-cit-0002","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/B978-0-444-52001-2.00022-4","article-title":"Immunosuppressive treatments in multiple sclerosis","volume":"122","author":"Okuda","year":"2014","journal-title":"Handb Clin Neurol"},{"issue":"13","key":"10.1002\/jcph.863-BIB0003|jcph863-cit-0003","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1056\/NEJM200009283431307","article-title":"Multiple sclerosis","volume":"343","author":"Noseworthy","year":"2000","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1002\/jcph.863-BIB0004|jcph863-cit-0004","doi-asserted-by":"crossref","first-page":"55","DOI":"10.7861\/clinmedicine.16-1-55","article-title":"Advances in pathogenesis and treatment of systemic sclerosis","volume":"16","author":"Denton","year":"2016","journal-title":"Clin Med"},{"issue":"4","key":"10.1002\/jcph.863-BIB0005|jcph863-cit-0005","doi-asserted-by":"crossref","first-page":"459","DOI":"10.4103\/0972-2327.165482","article-title":"Autologous hematopoietic stem cell transplantation in progressive severe multiple sclerosis","volume":"18","author":"Pandit","year":"2015","journal-title":"Ann Indian Acad Neurol"},{"key":"10.1002\/jcph.863-BIB0006|jcph863-cit-0006","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1046\/j.1529-8019.2002.01540.x","article-title":"Alkylating agents","volume":"15","author":"Germanas","year":"2002","journal-title":"Dermatol Ther"},{"issue":"4","key":"10.1002\/jcph.863-BIB0007|jcph863-cit-0007","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1080\/03602530500364023","article-title":"Metabolism and transport of oxazaphosphorines and the clinical implications","volume":"37","author":"Zhang","year":"2005","journal-title":"Drug Metab Rev"},{"issue":"1","key":"10.1002\/jcph.863-BIB0008|jcph863-cit-0008","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1158\/1078-0432.273.11.1","article-title":"Accuracy, feasibility, and clinical impact of prospective Bayesian pharmacokinetically guided dosing of cyclophosphamide, thiotepa, and carboplatin in high-dose chemotherapy","volume":"11","author":"Jonge","year":"2005","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1002\/jcph.863-BIB0009|jcph863-cit-0009","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.2217\/pgs.09.134","article-title":"Drug focus: pharmacogenetic studies related to cyclophosphamide-based therapy","volume":"10","author":"Pinto","year":"2009","journal-title":"Pharmacogenomics"},{"issue":"6","key":"10.1002\/jcph.863-BIB0010|jcph863-cit-0010","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/clpt.2009.27","article-title":"Personalized dosing of cyclophosphamide in the total body irradiation-cyclophosphamide conditioning regimen: a phase II trial in patients with hematologic malignancy","volume":"85","author":"McCune","year":"2009","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1002\/jcph.863-BIB0011|jcph863-cit-0011","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.clpt.2005.05.005","article-title":"Metabolism-based cyclophosphamide dosing for hematopoietic cell transplant","volume":"78","author":"McDonald","year":"2005","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"10.1002\/jcph.863-BIB0012|jcph863-cit-0012","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1182\/blood-2002-06-1860","article-title":"Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation","volume":"101","author":"McDonald","year":"2003","journal-title":"Blood"},{"key":"10.1002\/jcph.863-BIB0013|jcph863-cit-0013","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ejca.2015.12.007","article-title":"Cyclophosphamide pharmacokinetics and pharmacogenetics in children with B-cell non-Hodgkin's lymphoma","volume":"55","author":"Veal","year":"2016","journal-title":"Eur J Cancer"},{"issue":"9","key":"10.1002\/jcph.863-BIB0014|jcph863-cit-0014","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1038\/sj.bjc.6603097","article-title":"High exposures to bioactivated cyclophosphamide are related to the occurrence of veno-occlusive disease of the liver following high-dose chemotherapy","volume":"94","author":"Jonge","year":"2006","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1002\/jcph.863-BIB0015|jcph863-cit-0015","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3109\/08923978609026500","article-title":"Antitumor activity of optical isomers of cyclophosphamide, ifosfamide and trofosfamide as compared to clinically used racemates","volume":"8","author":"Ku\u015bnierczyk","year":"1986","journal-title":"J Immunopharmacol"},{"issue":"3","key":"10.1002\/jcph.863-BIB0016|jcph863-cit-0016","first-page":"285","article-title":"Comparative studies on biological activity of \/+\/R and \/-\/S enantiomers of cyclophosphamide and ifosfamide. II. Antiproliferative activity of cyclophosphamide and ifosfamide enantiomers","volume":"34","author":"Paprocka","year":"1986","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"10.1002\/jcph.863-BIB0017|jcph863-cit-0017","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1046\/j.1529-8019.2002.01540.x","article-title":"Alkylating agents","volume":"15","author":"Germanas","year":"2002","journal-title":"Dermatol Ther"},{"key":"10.1002\/jcph.863-BIB0018|jcph863-cit-0018","first-page":"2762","article-title":"Comparative metabolism of 2-[bis(2-chloroethyl)amino]tetrahydro-2-H-1,3,2-oxazaphosphorine-2-oxide (cyclophosphamide) and its enantiomers in humans","volume":"39","author":"Jarman","year":"1979","journal-title":"Cancer Res"},{"issue":"4","key":"10.1002\/jcph.863-BIB0019|jcph863-cit-0019","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s00280-011-1554-7","article-title":"Pharmacokinetics of cyclophosphamide enantiomers in patients with breast cancer","volume":"68","author":"Fernandes","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"10.1002\/jcph.863-BIB0020|jcph863-cit-0020","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1002\/chir.20596","article-title":"Determination of cyclophosphamide enantiomers in plasma by LC-MS\/MS: application to pharmacokinetics in breast cancer and lupus nephritis patients","volume":"21","author":"Miranda Silva","year":"2009","journal-title":"Chirality"},{"key":"10.1002\/jcph.863-BIB0021|jcph863-cit-0021","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/0378-4347(96)00085-0","article-title":"High-performance liquid chromatographic determination of the enantiomers of cyclophosphamide in serum","volume":"682","author":"Corlett","year":"1996","journal-title":"J. Chromatogr B Biomed Appl"},{"issue":"4","key":"10.1002\/jcph.863-BIB0022|jcph863-cit-0022","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/(SICI)1520-636X(1999)11:4<301::AID-CHIR7>3.0.CO;2-R","article-title":"Pharmacokinetics of (R)- and (S)-cyclophosphamide and their dechloroethylated metabolites in cancer patients","volume":"11","author":"Williams","year":"1999","journal-title":"Chirality"},{"issue":"7","key":"10.1002\/jcph.863-BIB0023|jcph863-cit-0023","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/(SICI)1520-636X(1999)11:7<569::AID-CHIR9>3.0.CO;2-R","article-title":"Enantioselective induction of cyclophosphamide metabolism by phenytoin","volume":"11","author":"Williams","year":"1999","journal-title":"Chirality"},{"key":"10.1002\/jcph.863-BIB0024|jcph863-cit-0024","first-page":"803","article-title":"Cyclophosphamide metabolism in children","volume":"55","author":"Yule","year":"1995","journal-title":"Cancer Res"},{"issue":"5","key":"10.1002\/jcph.863-BIB0025|jcph863-cit-0025","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1200\/JCO.1996.14.5.1484","article-title":"Conditioning regimen-dependent disposition of cyclophosphamide and hydroxycyclophosphamide in human marrow transplantation patients","volume":"14","author":"Slattery","year":"1996","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1002\/jcph.863-BIB0026|jcph863-cit-0026","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0009-9236(98)90178-3","article-title":"Pharmacokinetics of cyclophosphamide and its metabolites in bone marrow transplantation patients","volume":"64","author":"Ren","year":"1998","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1002\/jcph.863-BIB0027|jcph863-cit-0027","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1097\/FTD.0b013e318194e484","article-title":"Pharmacokinetics of cyclophosphamide and thiotepa in a conventional fractionated high-dose regimen compared with a novel simplified unfractionated regimen","volume":"31","author":"Ekhart","year":"2009","journal-title":"Ther Drug Monit"},{"issue":"5","key":"10.1002\/jcph.863-BIB0028|jcph863-cit-0028","first-page":"544","article-title":"Nonlinear pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide\/aldophosphamide in patients with metastatic breast cancer receiving high-dose chemotherapy followed by autologous bone marrow transplantation","volume":"25","author":"Chen","year":"1997","journal-title":"Drug Metab Dispos"},{"key":"10.1002\/jcph.863-BIB0029|jcph863-cit-0029","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jns.2010.08.053","article-title":"Imbalance in T-cell and cytokine profiles in patients with relapsing-remitting multiple sclerosis","volume":"300","author":"Mikulkova","year":"2011","journal-title":"J Neurol Sci"},{"issue":"5","key":"10.1002\/jcph.863-BIB0030|jcph863-cit-0030","doi-asserted-by":"crossref","first-page":"R147","DOI":"10.1186\/ar2821","article-title":"Plasma cytokine profiles in systemic sclerosis: associations with autoantibody subsets and clinical manifestations","volume":"11","author":"Gourh","year":"2009","journal-title":"Arthritis Res Ther"},{"issue":"4","key":"10.1002\/jcph.863-BIB0031|jcph863-cit-0031","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/clpt.2008.302","article-title":"Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics","volume":"85","author":"Morgan","year":"2009","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1002\/jcph.863-BIB0032|jcph863-cit-0032","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/clpt.2013.79","article-title":"A physiologically based pharmacokinetic modeling approach to predict disease-drug interactions: suppression of CYP3A by IL-6","volume":"94","author":"Machavaram","year":"2013","journal-title":"Clin Pharmacol Ther."},{"issue":"1-2","key":"10.1002\/jcph.863-BIB0033|jcph863-cit-0033","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jchromb.2006.03.022","article-title":"Rapid quantitation of cyclophosphamide metabolites in plasma by liquid chromatography-mass spectrometry","volume":"835","author":"Kalhorn","year":"2006","journal-title":"J Chromatogr B Anal Technol Biomed Life Sci."},{"key":"10.1002\/jcph.863-BIB0034|jcph863-cit-0034","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jchromb.2014.09.008","article-title":"Analysis of cyclophosphamide and carboxyethylphosphoramide mustard enantiomers in human plasma and application to clinical pharmacokinetics","volume":"971","author":"Atti\u00e9 de Castro","year":"2014","journal-title":"J Chromatogr B Anal Technol Biomed Life Sci."},{"key":"10.1002\/jcph.863-BIB0035|jcph863-cit-0035","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jchromb.2015.12.049","article-title":"Enantioselective analysis of 4-hydroxycyclophosphamide in human plasma with application to a clinical pharmacokinetic study","volume":"1011","author":"Castro","year":"2016","journal-title":"J Chromatogr B Anal Technol Biomed Life Sci."},{"issue":"3","key":"10.1002\/jcph.863-BIB0036|jcph863-cit-0036","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1093\/nar\/16.3.1215","article-title":"A simple salting out procedure for extracting DNA from human nucleated cells","volume":"16","author":"Miller","year":"1988","journal-title":"Nucleic Acids Res"},{"issue":"8","key":"10.1002\/jcph.863-BIB0037|jcph863-cit-0037","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1177\/0091270009337938","article-title":"Influence of glomerular filtration rate on the pharmacokinetics of cyclophosphamide enantiomers in patients with lupus nephritis","volume":"49","author":"Miranda Silva","year":"2009","journal-title":"J Clin Pharmacol"},{"issue":"10","key":"10.1002\/jcph.863-BIB0038|jcph863-cit-0038","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1136\/jnnp-2013-307207","article-title":"Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience","volume":"85","author":"Burman","year":"2014","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"6","key":"10.1002\/jcph.863-BIB0039|jcph863-cit-0039","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1097\/01.bor.0000434669.32150.ac","article-title":"Stem cell transplantation in systemic sclerosis","volume":"25","author":"Laar","year":"2013","journal-title":"Curr Opin Rheumatol"},{"issue":"9","key":"10.1002\/jcph.863-BIB0040|jcph863-cit-0040","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/bmt.2011.254","article-title":"Population pharmacokinetics of cyclophosphamide in patients with thalassemia major undergoing HSCT","volume":"47","author":"Balasubramanian","year":"2012","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"10.1002\/jcph.863-BIB0041|jcph863-cit-0041","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.2165\/00003088-200544110-00003","article-title":"Clinical pharmacokinetics of cyclophosphamide","volume":"44","author":"Jonge","year":"2005","journal-title":"Clin Pharmacokinet"},{"issue":"1-2","key":"10.1002\/jcph.863-BIB0042|jcph863-cit-0042","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jchromb.2007.04.024","article-title":"Simultaneous quantification of cyclophosphamide and its active metabolite 4-hydroxycyclophosphamide in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry (LC-MS\/MS)","volume":"854","author":"Ekhart","year":"2007","journal-title":"J Chromatogr B Anal Technol Biomed Life Sci"},{"issue":"1-2","key":"10.1002\/jcph.863-BIB0043|jcph863-cit-0043","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S0378-4347(99)00178-4","article-title":"Determination of cyclophosphamide and its metabolites in human plasma by high-performance liquid chromatography-mass spectrometry","volume":"729","author":"Baumann","year":"1999","journal-title":"J Chromatogr B Biomed Sci Appl"},{"issue":"3","key":"10.1002\/jcph.863-BIB0044|jcph863-cit-0044","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1097\/00007691-200206000-00013","article-title":"Simple method based on fluorescent detection for the determination of 4-hydroxycyclophosphamide in plasma","volume":"24","author":"Griskevicius","year":"2002","journal-title":"Ther Drug Monit"},{"issue":"3","key":"10.1002\/jcph.863-BIB0045|jcph863-cit-0045","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/j.1365-2125.2012.04223.x","article-title":"Cyclophosphamide and 4-hydroxycyclophosphamide pharmacokinetics in patients with glomerulonephritis secondary to lupus and small vessel vasculitis","volume":"74","author":"Joy","year":"2012","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"10.1002\/jcph.863-BIB0046|jcph863-cit-0046","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/j.1472-8206.2000.tb00424.x","article-title":"Pharmacokinetics of cyclophosphamide (CP) and 4-OH-CP\/aldophosphamide in systemic vasculitis","volume":"14","author":"Belfayol-Pisant\u00e9","year":"2000","journal-title":"Fundam Clin Pharmacol"},{"issue":"4","key":"10.1002\/jcph.863-BIB0047|jcph863-cit-0047","doi-asserted-by":"crossref","first-page":"78380","DOI":"10.1155\/MI\/2006\/78380","article-title":"The levels of ghrelin, leptin, TNF-alpha, and IL-6 in liver cirrhosis and hepatocellular carcinoma due to HBV and HDV infection","volume":"2006","author":"Ataseven","year":"2006","journal-title":"Mediators Inflamm"},{"issue":"5","key":"10.1002\/jcph.863-BIB0048|jcph863-cit-0048","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1155\/MI.2005.273","article-title":"Serum levels of TNF-\u03b1, IFN-\u03b3, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity","volume":"2005","author":"Arican","year":"2005","journal-title":"Mediators Inflamm"},{"issue":"9","key":"10.1002\/jcph.863-BIB0049|jcph863-cit-0049","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/oby.2000.86","article-title":"Raised interleukin-6 levels in obese patients","volume":"8","author":"Roytblat","year":"2000","journal-title":"Obes Res"},{"issue":"8","key":"10.1002\/jcph.863-BIB0050|jcph863-cit-0050","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1124\/dmd.111.038679","article-title":"Effects of interleukin-6 (IL-6) and an anti-IL-6 monoclonal antibody on drug-metabolizing enzymes in human hepatocyte culture","volume":"39","author":"Dickmann","year":"2011","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1002\/jcph.863-BIB0051|jcph863-cit-0051","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.clpt.2004.03.002","article-title":"CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians","volume":"76","author":"Vianna-Jorge","year":"2004","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1002\/jcph.863-BIB0052|jcph863-cit-0052","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ejps.2005.08.008","article-title":"Pharmacogenetics of cyclophosphamide in patients with hematological malignancies","volume":"27","author":"Xie","year":"2006","journal-title":"Eur J Pharm Sci"},{"issue":"8","key":"10.1002\/jcph.863-BIB0053|jcph863-cit-0053","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1007\/s00228-013-1507-7","article-title":"Population pharmacokinetics analysis of cyclophosphamide with genetic effects in patients undergoing hematopoietic stem cell transplantation","volume":"69","author":"Kim","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"10.1002\/jcph.863-BIB0054|jcph863-cit-0054","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1124\/dmd.111.039347","article-title":"Potential contribution of cytochrome P450 2B6 to hepatic 4-hydroxycyclophosphamide formation in vitro and in vivo","volume":"40","author":"Raccor","year":"2012","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"10.1002\/jcph.863-BIB0055|jcph863-cit-0055","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1124\/jpet.103.059105","article-title":"ABCC2-mediated biliary transport of 4-glutathionylcyclophosphamide and its contribution to elimination of 4-hydroxycyclophosphamide in rat","volume":"308","author":"Qiu","year":"2004","journal-title":"J Pharmacol Exp Ther"}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjcph.863","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/jcph.863","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T12:14:05Z","timestamp":1749903245000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/jcph.863"}},"subtitle":["The Journal of Clinical Pharmacology"],"short-title":[],"issued":{"date-parts":[[2017,1,13]]},"references-count":55,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"URL":"https:\/\/doi.org\/10.1002\/jcph.863","archive":["Portico"],"relation":{},"ISSN":["0091-2700"],"issn-type":[{"value":"0091-2700","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1,13]]}}}